[Form 4] INTUITIVE SURGICAL INC Insider Trading Activity

Rhea-AI Filing Summary

Intuitive Surgical (ISRG) executive Henry L. Charlton reported option exercises and open‑market sales on 11/12/2025 under a Rule 10b5‑1 trading plan. He exercised options for 636, 2,565, 2,898, and 2,901 shares at exercise prices of $347.4167, $245.6, $242.3367, and $177.9867, respectively, and reported multiple sales at $580 per share. Following the transactions, he directly owns 3,056 shares. The plan is stated to expire on June 1, 2026.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Charlton Henry L

(Last) (First) (Middle)

1020 KIFER ROAD

(Street)

SUNNYVALE CA 94086

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INTUITIVE SURGICAL INC [ ISRG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Commercial and Mkt

3. Date of Earliest Transaction (Month/Day/Year)
11/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/12/2025		M(1)		636	A	$347.4167	8,423	D
Common Stock	11/12/2025		S(1)		636	D	$580	7,787	D
Common Stock	11/12/2025		M(1)		2,565	A	$245.6	10,352	D
Common Stock	11/12/2025		S(1)		2,565	D	$580	7,787	D
Common Stock	11/12/2025		M(1)		2,898	A	$242.3367	10,685	D
Common Stock	11/12/2025		S(1)		2,898	D	$580	7,787	D
Common Stock	11/12/2025		M(1)		2,901	A	$177.9867	10,688	D
Common Stock	11/12/2025		S(1)		2,901	D	$580	7,787	D
Common Stock	11/12/2025		S(1)		4,731	D	$580	3,056	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$177.9867	11/12/2025		M(1)			2,901	(2)	02/28/2030	Common Stock	2,901	$0.0	0	D
Non-Qualified Stock Option (right to buy)	$242.3367	11/12/2025		M(1)			2,898	(3)	08/28/2030	Common Stock	2,898	$0.0	0	D
Non-Qualified Stock Option (right to buy)	$245.6	11/12/2025		M(1)			2,565	(2)	02/26/2031	Common Stock	2,565	$0.0	0	D
Non-Qualified Stock Option (right to buy)	$347.4167	11/12/2025		M(1)			636	(3)	08/26/2031	Common Stock	636	$0.0	1,929	D

Explanation of Responses:

1. The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on June 1, 2026.

2. Non-statutory stock option granted pursuant to the 2010 Incentive Awards Plan. The option vests 1/8th six months after the date of grant and 1/48th monthly thereafter.

3. Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. Option shall vest 7/48 one month after the date of grant and 1/48 each month thereafter.

	By: Thanh Nhan Phan For: Charlton, Henry L	11/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ISRG insider Henry L. Charlton report on Form 4?

He reported option exercises and sales on 11/12/2025 conducted under a Rule 10b5‑1 trading plan.

How many ISRG shares does the insider hold after the transactions?

He directly holds 3,056 shares following the reported trades.

What were the option exercise prices disclosed?

Exercises were at $177.9867, $242.3367, $245.6, and $347.4167 per share.

At what price were ISRG shares sold?

Reported sales were executed at $580 per share.

Was the trading under a Rule 10b5-1 plan?

Yes. The filing states the trades were under a Rule 10b5‑1 plan that expires on June 1, 2026.

What is the insider’s role at Intuitive Surgical (ISRG)?

He is an Officer, serving as EVP & Chief Commercial and Mkt.

Were any derivative holdings remaining after exercises?

Table II shows 1,929 derivative securities beneficially owned following the reported transactions.